Cargando…
DNA Methylation Biomarkers for Prediction of Response to Platinum-Based Chemotherapy: Where Do We Stand?
SIMPLE SUMMARY: Platinum-based agents are one of the most widely used chemotherapy drugs for various types of cancer. However, one of the main challenges in the application of platinum drugs is resistance, which is currently being widely investigated. Epigenetic DNA methylation-based biomarkers are...
Autores principales: | Tavares, Nuno Tiago, Gumauskaitė, Saulė, Lobo, João, Jerónimo, Carmen, Henrique, Rui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221086/ https://www.ncbi.nlm.nih.gov/pubmed/35740584 http://dx.doi.org/10.3390/cancers14122918 |
Ejemplares similares
-
The toxicity of methyl isocyanate: Where do we stand?
por: Bucher, John R.
Publicado: (1987) -
Novel radionuclides for use in Nuclear Medicine in Europe: where do we stand and where do we go?
por: Radzina, Maija, et al.
Publicado: (2023) -
Where Do We Stand?
Publicado: (1891) -
Dupuytren’s disease: where do we stand?
por: Grazina, Rita, et al.
Publicado: (2019) -
Biomarkers for Alzheimer’s Disease: Where Do We Stand and Where Are We Going?
por: Villa, Chiara
Publicado: (2020)